Using the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) to measure the therapeutic effects of risperidone.
Using the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) to measure the therapeutic effects of risperidone.
复制标题
使用严重残疾人诊断评估-II (DASH-II) 来衡量利培酮的治疗效果。
DOI：
10.1111/j.1365-2788.2004.00583.x
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
Schroeder,SR
中科院分区：
文献类型：
--
作者：
Valdovinos,MG;Zarcone,JR;Hellings,JA;Kim,G;Schroeder,SR
背景在一项双盲、安慰剂对照、交叉药物研究的范围内，严重残疾人诊断评估-II（DASH-II）被评估为确定药物利培酮治疗21名智力残疾人（ID）问题行为的有效性的测量方法。在研究的基线阶段和研究的维持阶段，并在整个研究期间每周完成异常行为检查表-社区（ABC-C）。将使用DASH‐II获得的结果与使用ABC‐C获得的结果进行比较，ABC ‐ C是一种与DASH‐II具有良好相关性的工具。结果结果表明，虽然DASH‐II和ABC‐C在当前研究的安慰剂/基线阶段具有良好相关性，但在药物试验的6个月维持阶段完成时，它们并不具有良好相关性。虽然适用于协助诊断ID患者的精神病理学，但似乎不能监测使用利培酮以及ABC‐C导致的问题行为变化。讨论了每种测量方法评估的问题行为频率的差异以及使用DASH‐II测量药物对问题行为影响的适用性。
BackgroundWithin the scope of a double‐blind, placebo‐controlled, crossover medication study, the Diagnostic Assessment of the Severely Handicapped‐II (DASH‐II) was evaluated as a measurement for determining the effectiveness of the medication risperidone in treating the problem behaviour of 21 people with intellectual disabilities (ID).MethodParticipants’ caregivers completed the DASH‐II during the placebo/baseline phase of the study and the maintenance phase of the study, and completed the Aberrant Behavior Checklist – Community (ABC‐C) weekly throughout the entire study. The results obtained using the DASH‐II were compared to those obtained using the ABC‐C, an instrument shown to be well correlated with the DASH‐II.ResultsResults suggest that while the DASH‐II and the ABC‐C were well correlated during the placebo/baseline phase of the current study, they were not well correlated at completion of the 6‐month maintenance phase of the medication trial.ConclusionThe DASH‐II, while appropriate for assisting in the diagnosis of psychopathology in people with ID, does not appear to monitor changes in problem behaviour as a result of risperidone use as well as the ABC‐C. Differences in the frequency of problem behaviour that each measure evaluated and the applicability of using the DASH‐II to measure medication effects on problem behaviour are discussed.